CM Management LLC Sells 6,000 Shares of IQVIA Holdings Inc. $IQV

CM Management LLC decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 50.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,000 shares of the medical research company’s stock after selling 6,000 shares during the period. CM Management LLC’s holdings in IQVIA were worth $1,140,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Eubel Brady & Suttman Asset Management Inc. purchased a new stake in IQVIA during the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC boosted its stake in shares of IQVIA by 33.6% in the 3rd quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock worth $8,800,000 after buying an additional 11,657 shares during the last quarter. OPTIMAS CAPITAL Ltd bought a new stake in shares of IQVIA in the third quarter worth $4,008,000. Amundi increased its position in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after acquiring an additional 405,250 shares during the last quarter. Finally, EDENTREE ASSET MANAGEMENT Ltd bought a new position in IQVIA in the third quarter valued at about $7,368,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on IQV. Mizuho set a $215.00 price target on IQVIA in a research note on Monday, February 23rd. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a report on Friday, February 6th. Morgan Stanley set a $240.00 target price on shares of IQVIA in a research report on Wednesday, February 11th. TD Cowen increased their price target on shares of IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $231.13.

IQVIA Price Performance

Shares of NYSE:IQV opened at $174.56 on Friday. The company has a market capitalization of $29.62 billion, a P/E ratio of 22.21, a P/E/G ratio of 1.68 and a beta of 1.39. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The firm’s 50 day simple moving average is $207.22 and its two-hundred day simple moving average is $207.47. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same period in the prior year, the company posted $3.12 earnings per share. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.